Nifty settles below 9,800, down over 1.5% for the week; Sensex ends flat
Catch all that happened in the market here
 "Photo: Shutterstock")
Photo: Shutterstock
Benchmark indices pared gains to end flat, losing over 1.5% in the week on foreign fund outflows amid worries that the government may widen its fiscal deficit target of 3.2% of gross domestic product for the year ending in March 2018 to boost an economy that grew at a slower pace than expected.
Foreign investors net selling equities worth $1.1 billion during the month. They had sold worth $2 billion in shares in August.
Markets saw a tough month in September as a slew of negative global and domestic factors, including expectations of further rate hikes by the US Federal Reserve and a weaker-than-expected economic growth at home, hit sentiment.
Foreign investors net selling equities worth $1.1 billion during the month. They had sold worth $2 billion in shares in August.
Markets saw a tough month in September as a slew of negative global and domestic factors, including expectations of further rate hikes by the US Federal Reserve and a weaker-than-expected economic growth at home, hit sentiment.
Meanwhile, the rupee also strengthened to as much as 65.28 per dollar, but was still down over 2% for the month against the dollar, its biggest monthly decline since November 2016.
Globally, Asian shares regained some poise after a tough week in which the gathering risk of a US rate rise lifted Treasury yields toward nine-year highs and left the dollar on track for its best week so far this year.
3:46 PM
Market rundown by Anand James, Chief Market Strategist at Geojit Financial Services
Government's decision to stick to its budgeted borrowing limit eased the nerves of the investors and bargain hunting in the recently trampled stocks gave impetus to the domestic indices. Positivity from global markets, also added more legs to yesterday’s f&o related short covering, but with a long weekend ahead, followed by RBI rate decision and a series of macro data, traders opted to limit aggressive bets.
3:45 PM
Nifty Chart for the day
Source: NSE
3:41 PM
Nifty Realty was the top sectoral gainer, up 2.6%
Source: NSE
3:39 PM
Sectoral Trend
Source: NSE
3:37 PM
Top Sensex gainers and losers
Source: BSE
3:35 PM
Broader Markets
Broader markets outperformed benchmark indices with BSE Midcap and BSE smallcap indices gaining 0.8% and 1% respectively. Both indices ended over 1% for the week
Broader markets outperformed benchmark indices with BSE Midcap and BSE smallcap indices gaining 0.8% and 1% respectively. Both indices ended over 1% for the week
3:33 PM
Markets at close
Benchmark indices pared gains to end flat, losing over 1.5% in the week on foreign fund outflows amid worries that the government may widen its fiscal deficit target of 3.2% of gross domestic product for the year ending in March 2018 to boost an economy that grew at a slower pace than expected.
The S&P BSE Sensex ended the day at 31,283, up 1 point while the broader Nifty50 index settled at 9,788 up 19 points
Benchmark indices pared gains to end flat, losing over 1.5% in the week on foreign fund outflows amid worries that the government may widen its fiscal deficit target of 3.2% of gross domestic product for the year ending in March 2018 to boost an economy that grew at a slower pace than expected.
The S&P BSE Sensex ended the day at 31,283, up 1 point while the broader Nifty50 index settled at 9,788 up 19 points
3:22 PM
FMCG sector slips over 1%
Source: NSE
3:14 PM
Buzzing Stocks
MEP Infrastructure Developers surged 5.58% to Rs 102.10 on BSE after the company said it has secured a contract for collection of toll at all entry points to Delhi.
MEP Infrastructure Developers surged 5.58% to Rs 102.10 on BSE after the company said it has secured a contract for collection of toll at all entry points to Delhi.
3:05 PM
USFDA Nod
Drug firm Zydus Cadila has received final approval from the US health regulator to market doxycycline tablets, used for treatment of different types of bacterial infections such as acne and eye infection.
The company has received approval from the US Food and Drug Administration (USFDA) to market the drug in strengths of 50 mg, 75 mg, 100 mg and 150 mg, Zydus Cadila said in a BSE filing today.
Topics :
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Sep 29 2017 | 3:31 PM IST